Amid conflicting reports on the need for COVID-19 vaccine boosters, the FDA's advisory committee will be reviewing the current information on the Pfizer shot on Friday before issuing its own opinion. Dr. William Schaffner, MD, professor of infectious diseases at Vanderbilt Medical Center, joined Cheddar to break down the process and the likelihood for a go-ahead from the regulatory agency. "It's a very simple decision, actually. I think we'll see some debate in its advisory committee, but my crystal ball suggests that the data are strong enough such that the FDA will approve it." Should that happen, the CDC's advisory committee would then take up the issue of "who should get the booster, when, and under what circumstances."